At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
fosaprepitant dimegluminedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prevention of Nausea and Vomiting Secondary to FOLFIRINOX Chemotherapy in Gastrointestinal Cancer Patients
In Brief
A clinical study evaluating fosaprepitant dimeglumine for Gastrointestinal Cancer and Nausea Post Chemotherapy. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This clinical trial studies fosaprepitant dimeglumine in preventing nausea and vomiting in patients with gastrointestinal cancer receiving combination chemotherapy. Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Cancer, Nausea Post Chemotherapy
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartJun 2012
Primary CompletionDec 2016
Study CompletionSep 2020
TodayJul 2026
First PostedJan 5, 2012
Enrollment StartJun 1, 2012
Primary CompletionDec 29, 2016
Study CompletionSep 3, 2020
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 14.5 years ago
Interventions
fosaprepitant dimegluminedrug
Given IV